1
|
Instituto Nacional de Estadística y
Geografía (INEGI). Webpage. http://www.inegi.org.mx/July 12–2018
|
2
|
Shi SS, Shi CC, Zhao ZY, Shen HQ, Fang XM,
Tan LH, Zhang XH, Shi Z, Lin R and Shu Q: Effect of open heart
surgery with cardiopulmonary bypass on peripheral blood lymphocyte
apoptosis in children. Pediatr Cardiol. 30:153–159. 2009.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Laffey JG, Boylan JF and Cheng DC: The
systemic inflammatory response to cardiac surgery: Implications for
the anesthesiologist. Anesthesiology. 97:215–252. 2002. View Article : Google Scholar : PubMed/NCBI
|
4
|
Stark J, Gallivan S, Lovegrove J, Hamilton
JR, Monro JL, Pollock JC and Watterson KG: Mortality rates after
surgery for congenital heart defects in children and surgeons'
performance. Lancet. 355:1004–1007. 2000. View Article : Google Scholar : PubMed/NCBI
|
5
|
Markewitz A, Faist E, Lang S, Endres S,
Fuchs D and Reichart B: Successful restoration of cell-mediated
immune response after cardiopulmonary bypass by immunomodulation. J
Thorac Cardiovasc Surg. 105:15–24. 1993. View Article : Google Scholar : PubMed/NCBI
|
6
|
Hisatomi K, Isomura T, Kawara T, Yamashita
M, Hirano A, Yoshida H, Eriguchi N, Kosuga K and Ohishi K: Changes
in lymphocyte subsets, mitogen responsiveness, and interleukin-2
production after cardiac operations. J Thorac Cardiovasc Surg.
98:580–591. 1989. View Article : Google Scholar : PubMed/NCBI
|
7
|
Chello M, Mastroroberto P, Quirino A, Cuda
G, Perticone F, Cirillo F and Covino E: Inhibition of neutrophil
apoptosis after coronary bypass operation with cardiopulmonary
bypass. Ann Thorac Surg. 73:123–130. 2002. View Article : Google Scholar : PubMed/NCBI
|
8
|
Habermehl P, Knuf M, Kampmann C, Mannhardt
W, Schranz D, Kuroczynski W, Wippermann CF and Zepp F: Changes in
lymphocyte subsets after cardiac surgery in children. Eur J
Pediatr. 162:15–21. 2003. View Article : Google Scholar : PubMed/NCBI
|
9
|
Wesche DE, Lomas-Neira JL, Perl M, Chung
CS and Ayala A: Leukocyte apoptosis and its significance in sepsis
and shock. J Leukoc Biol. 78:325–337. 2005. View Article : Google Scholar : PubMed/NCBI
|
10
|
Hotchkiss RS, Swanson PE, Knudson CM,
Chang KC, Cobb JP, Osborne DF, Zollner KM, Buchman TG, Korsmeyer SJ
and Karl IE: Overexpression of Bcl-2 in transgenic mice decreases
apoptosis and improves survival in sepsis. J Immunol.
162:4148–4156. 1999.PubMed/NCBI
|
11
|
Calandra T and Cohen J; International
Sepsis Forum Definition of Infection in the ICU Consensus
Conference, : The international sepsis forum consensus conference
on definitions of infection in the intensive care unit. Crit Care
Med. 33:1538–1548. 2005. View Article : Google Scholar : PubMed/NCBI
|
12
|
Goldstein B, Giroir B and Randolph A;
International Consensus Conference on Pediatric Sepsis, :
International pediatric sepsis consensus conference: Definitions
for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care
Med. 6:2–8. 2005. View Article : Google Scholar : PubMed/NCBI
|
13
|
Szabo G, Romics L Jr and Frendl G: Liver
in sepsis and systemic inflammatory response syndrome. Clin Liver
Dis. 6:1045–1066. 2002. View Article : Google Scholar : PubMed/NCBI
|
14
|
Takeda K and Akira S: Toll-like receptors
in innate immunity. Int Immunol. 17:1–14. 2005. View Article : Google Scholar : PubMed/NCBI
|
15
|
Bianchi ME: DAMPs, PAMPs and alarmins: All
we need to know about danger. J Leukoc Biol. 81:1–5. 2007.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Guha M and Mackman N: LPS induction of
gene expression in human monocytes. Cell Signal. 13:85–94. 2001.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Lin M and Rikihisa Y: Ehrlichia
chaffeensis downregulates surface Toll-like receptors 2/4, CD14 and
transcription factors PU.1 and inhibits lipopolysaccharide
activation of NF-kappaB, ERK 1/2 and p38 MAPK in host monocytes.
Cell Microbiol. 6:175–186. 2004. View Article : Google Scholar : PubMed/NCBI
|
18
|
Opal SM: The host response to endotoxin,
antilipopolysaccharide strategies, and the management of severe
sepsis. Int J Med Microbiol. 297:365–377. 2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Lien E and Ingalls RR: Toll-like
receptors. Crit Care Med. 30 (Suppl 1):S1–S11. 2002. View Article : Google Scholar
|
20
|
Wang JE, Jørgensen PF, Almlöf M,
Thiemermann C, Foster SJ, Aasen AO and Solberg R: Peptidoglycan and
lipoteichoic acid from Staphylococcus aureus induce tumor necrosis
factor alpha, interleukin 6 (IL-6), and IL-10 production in both T
cells and monocytes in a human whole blood model. Infect Immun.
68:3965–3970. 2000. View Article : Google Scholar : PubMed/NCBI
|
21
|
Pålsson-McDermott EM and O'Neill LA:
Signal transduction by the lipopolysaccharide receptor, Toll-like
receptor-4. Immunology. 113:153–162. 2004. View Article : Google Scholar : PubMed/NCBI
|
22
|
Shimaoka M and Park EJ: Advances in
understanding sepsis. Eur J Anaesthesiol Suppl. 42:146–153. 2008.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Weigand MA, Hörner C, Bardenheuer HJ and
Bouchon A: The systemic inflammatory response syndrome. Best Pract
Res Clin Anaesthesiol. 18:455–475. 2004. View Article : Google Scholar : PubMed/NCBI
|
24
|
Li S, Price R, Phiroz D, Swan K and Crane
TA: Systemic inflammatory response during cardiopulmonary bypass
and strategies. J Extra Corpor Technol. 37:180–188. 2005.PubMed/NCBI
|
25
|
Day JR and Taylor KM: The systemic
inflammatory response syndrome and cardiopulmonary bypass. Int J
Surg. 3:129–140. 2005. View Article : Google Scholar : PubMed/NCBI
|
26
|
Castellheim A, Brekke OL, Espevik T,
Harboe M and Mollnes TE: Innate immune responses to danger signals
in systemic inflammatory response syndrome and sepsis. Scand J
Immunol. 69:479–491. 2009. View Article : Google Scholar : PubMed/NCBI
|
27
|
Aldemir M, Baki ED, Adali F, Çarşanba G,
Tecer E and Taş HU: Comparison of neutrophil:lymphocyte ratios
following coronary artery bypass surgery with or without
cardiopulmonary bypass. Cardiovasc J Afr. 26:159–164. 2015.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Itoh H, Ichiba S, Ujike Y, Douguchi T,
Kasahara S, Arai S and Sano S: A prospective randomized trial
comparing the clinical effectiveness and biocompatibility of
heparin-coated circuits and PMEA-coated circuits in pediatric
cardiopulmonary bypass. Perfusion. 31:247–254. 2016. View Article : Google Scholar : PubMed/NCBI
|
29
|
Khabar KS, elBarbary MA, Khouqeer F, Devol
E, al-Gain S and al-Halees Z: Circulating endotoxin and cytokines
after cardiopulmonary bypass: Differential correlation with
duration of bypass and systemic inflammatory response/multiple
organ dysfunction syndromes. Clin Immunol Immunopathol. 85:97–103.
1997. View Article : Google Scholar : PubMed/NCBI
|
30
|
Miller BE and Levy JH: The inflammatory
response to cardiopulmonary bypass. J Cardiothorac Vasc Anesth.
11:355–366. 1997. View Article : Google Scholar : PubMed/NCBI
|
31
|
Meldrum DR: Tumor necrosis factor in the
heart. Am J Physiol. 274:R577–R595. 1998.PubMed/NCBI
|
32
|
Hill GE: Cardiopulmonary bypass-induced
inflammation: Is it important? J Cardiothorac Vasc Anesth. 12 (2
Suppl 1):S21–S25. 1998.
|